Heron Therapeutics Inc HRTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/02/21 EST
17.68UNCH (UNCH)
Volume
15,726
Close
17.68quote price arrow down-0.41 (-2.27%)
Volume
651,193
52 week range
9.60 - 22.40

...

Loading . . .

KEY STATS

  • Open18.01
  • Day High18.21
  • Day Low17.66
  • Prev Close17.68
  • 52 Week High22.40
  • 52 Week High Date12/28/20
  • 52 Week Low9.60
  • 52 Week Low Date03/16/20
  • Market Cap1.616B
  • Shares Out91.40M
  • 10 Day Average Volume0.89M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • 1 Year % Change-3.39

RATIOS/PROFITABILITY

  • EPS (TTM)-2.50
  • P/E (TTM)-7.06
  • Fwd P/E (NTM)-7.90
  • EBITDA (MRQ)-225.316M
  • ROE (MRQ)-70.99%
  • Revenue (MRQ)88.64M
  • Gross Margin (MRQ)59.17%
  • Net Margin (MRQ)-256.41%
  • Debt To Equity (MRQ)2.98%

EVENTS

  • Earnings Date05/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Heron Therapeutics Inc News

There is no recent news for this security.

Latest HRTX News From Our Partners

QUOTE FINDER

Profile

MORE
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed...
Barry Quart Pharm.D.
Chairman
John Poyhonen
President
David Szekeres
Chief Operating Officer
Lisa Peraza
Chief Accounting Officer
Kimberly Manhard
Executive Vice President
John Arthur Ph.D.
Vice President
Address
4242 Campus Point Ct Ste 200
San Diego, CA
92121
United States